AUTL Stock Summary and Trading Ideas (Autolus Therapeutics PLC - American Depositary Shares | NASDAQ:AUTL)

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AUTL.

As of April 25, 2024, AUTL stock price declined to $4.08 with 3,835,111 million shares trading.

AUTL has a beta of 3.41, meaning it tends to be more sensitive to market movements. AUTL has a correlation of 0.22 to the broad based SPY ETF.

AUTL has a market cap of $1.08 billion. This is considered a Small Cap stock.

In the last 3 years, AUTL stock traded as high as $8.23 and as low as $1.60.

The top ETF exchange traded funds that AUTL belongs to (by Net Assets): IBB, INNO, GWX, CNCR, BIB.

AUTL has outperformed the market in the last year with a return of +129.2%, while the SPY ETF gained +23.6%. However, in the most recent history, AUTL shares have underperformed the stock market with its stock returning -28.9% in the last 3 month period and -20.8% for the last 2 week period, while SPY has returned +4.1% and -2.1%, respectively.

AUTL support price is $4.01 and resistance is $4.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUTL stock will trade within this expected range on the day.